NONMYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) FROM HLA-MATCHED RELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES: CLINICAL RESULTS OF A TBI-BASED CONDITIONING REGIMEN
Bm Sandmaier, R Strob, Ute Hegenbart(Heidelberg University), D Niederwieser(University Hospital of Basel), Bénedicte Bruno(Centre Hospitalier Universitaire de Lille), Peter A. McSweeney(Mesoblast (United States)), Judith A. Shizuru(Stanford University), E.D. Agura, Karl G. Blume(City Of Hope National Medical Center), Ted Gooley, T Chauncey, DG Maloney, Stephen J. Forman(City of Hope), Firoozeh Sahebi(City Of Hope National Medical Center)
Blood
January 1, 2001
Cited by 39
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k